Michael Hallek: PET-guided BrECADD versus eBEACOPP in Hodgkin lymphoma
Michael Hallek, Director of Clinic I for Internal Medicine and Associated Principle Investigator at the University Hospital Cologne, shared on X:
“PET-guided BrECADD versus eBEACOPP in Hodgkin lymphoma (HD21 trial): PET-2-guided BrECADD shows high efficacy with improved tolerability, surpassing that of eBEACOPP. BrECADD = new 1L standard treatment for adult patients with advanced Hodgkin lymphoma.
‘Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial‘ Published in the Lancet
Authors: Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Sebastian Scholl, Max S Topp, Wolfram Jung, Vladan Vucinic, Hans-Joachim Beck, Andrea Kerkhoff, Benjamin Unger, Andreas Rank, Roland Schroers, Christian Meyer zum Büschenfelde, Maike de Wit, Karolin Trautmann-Grill, Peter Kamper, Daniel Molin, Stefanie Kreissl, Helen Kaul, Dipl-Math, Bastian von Tresckow, Sven Borchmann, Karolin Behringer, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans-Theodor Eich, Christian Baues, Athanasios Zomas, Michael Hallek, Markus Dietlein, Carsten Kobe, Volker Diehl.”
Source: Michael Hallek/X